Recent patents in the discovery of small molecule inhibitors of JAK3.
BACKGROUND
Protein kinase enzymes have become increasingly important as the target of many disease modification drug discovery programs. Disruption of JAK3 function results in quantitative and qualitative deficiencies in both B- and T-cell compartments of the immune system of JAK3 deficient mice and development of severe combined immunodeficiency in humans with the JAK3 genetic aberration. JAK3 plays a specific role in immune function and lymphoid development and it only resides in the hematopoietic system, thus the rationale for selective targeting. Inhibitors of JAK3 have shown utility in many different autoimmune disorders, including allograft rejection during transplantation, acute lymphoblastic leukemia, Type 1 diabetes, rheumatoid arthritis and allergic and asthmatic diseases. These inhibitors are making their way into clinical trials with profound effects, thus, validating the target and strategy.


METHODS
A review that covers around 90 patents and patent applications made in the last 10 years in the area involving JAK3 inhibitors is provided. Specifically, what this content will provide is the genus, highlighted compounds of particular interest, filing organization and some biological measure of these compounds as inhibitors of this protein kinase or none if it is not provided. Some information from original research articles appearing in peer reviewed literature is provided, but this article is not a review of the literature. Furthermore, an overview of the current clinical status and future outcomes of this field is provided as summary.


RESULTS
A strong understanding for the current state of the art in patents dealing with inhibitors of JAK3 including genus and species designations, potential commercial interest of this target in the pharmaceutical community, depth of coverage by numbers of examples and selected proof of action against the target. Also, a brief understanding of the biology and pharmacology involved in the processes involving the research, discovery, characterization and clinical status of JAK3 inhibitors.


CONCLUSIONS
This review is intended for medicinal chemists and patent agents who want to get a quick understanding of the state of the art in the field of JAK3 inhibitors. It further serves as a reference point to go into more depth on any series reported and to be able to evaluate any original research ideas in this area in the future.
Wilson
Lawrence J
LJ
Emory University, Emory Institute for Drug Discovery, 1521 Dickey Drive, Atlanta, GA 30322, USA. wilsonlarr@gmail.com
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000201:enzymology; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D053616:Janus Kinase 3 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D051379:Mice; D010330:Patents as Topic; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use
D047428:Protein Kinase Inhibitors; D053616:Janus Kinase 3